Day 14 Splenocyte Responses to Host Alloantigens In Vitro
| Treatment Group | MLC | CTL Activity (%Lysis) | ||||
| Proliferation (cpm × 103) | IL-2 Production (U/mL) | E:T = 25:1 | ||||
| Stimulators | Targets | |||||
| B6D2F1 | B6 | B6D2F1 | B6 | P815 | EL4 | |
| KGF | 23.9 ± 1.5 | 5.26 ± 0.75 | 1.23 ± 0.18 | UD | 31.6 ± 3.4 | 3.8 ± 1.9 |
| Control | 18.8 ± 0.5 | 1.70 ± 0.10 | 1.20 ± 0.20 | UD | 35.0 ± 2.1 | 3.7 ± 2.1 |
| Treatment Group | MLC | CTL Activity (%Lysis) | ||||
| Proliferation (cpm × 103) | IL-2 Production (U/mL) | E:T = 25:1 | ||||
| Stimulators | Targets | |||||
| B6D2F1 | B6 | B6D2F1 | B6 | P815 | EL4 | |
| KGF | 23.9 ± 1.5 | 5.26 ± 0.75 | 1.23 ± 0.18 | UD | 31.6 ± 3.4 | 3.8 ± 1.9 |
| Control | 18.8 ± 0.5 | 1.70 ± 0.10 | 1.20 ± 0.20 | UD | 35.0 ± 2.1 | 3.7 ± 2.1 |
CTL activity or proliferation and IL-2 production (in MLC) was determined as described in Materials and Methods. KGF or control was given from day −3 to +7. The stimulation index (the ratio of proliferation to host stimulators to proliferation to syngeneic stimulators) was 11.0 in controls and 4.6 in KGF-treated allogeneic BMT recipients. The cytolytic activity was equivalent in KGF- and control-treated animals at all effector to target (E:T) ratios tested (from 1.6:1 to 25:1). Data represent mean ± SD of triplicate wells from one of three similar experiments.
Abbreviation: UD, under the level of detection.